Last updated: May 18, 2016
|CMS Measure ID:||CMS141v4|
Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.
|Initial Patient Population:||
All patients aged 18 through 80 years with colon cancer
Equals Initial Patient Population with AJCC Stage III colon cancer
Patients who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or who have previously received adjuvant chemotherapy within the 12 month reporting period
|Measure Steward:||American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)|
|Domain:||Effective Clinical Care|
|Next Version:||Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients|
Higher score indicates better quality
The measure logic includes the combination of 5-FU/LV/oxaliplatin which will capture either mFOLFOX6 or FLOX, category 1, as referenced in the definitions section.
The denominator for this measure has been limited to patients with a first recorded colon cancer diagnosis during the 12 month reporting period. The numerator captures patients who are prescribed adjuvant chemotherapy or received adjuvant chemotherapy during the 12 month period. Referred for Chemotherapy is not separately specified, as this option can be captured either through the Medication Order: Chemotherapy for Colon Cancer numerator option or the patient reason exception: Medication, Administered not done: Patient reason for Chemotherapy for Colon Cancer. Additional valid medical reason exceptions might include acute renal insufficiency, neutropenia, or leukopenia. Date of diagnosis is defined as the date of pathologic diagnosis.
The requirement of Count >=2 of Encounter, Performed is to establish that the eligible professional has an existing relationship with the patient.